Abstract:Chimeric antigen receptor (CAR) T-cell therapy entails the genetic engineering of a patient's T-cells to express membrane spanning fusion receptors with defined specificities for tumor-associated antigens. These CARs are capable of eliciting robust T-cell activation to initiate killing of the target tumor cells. This therapeutic approach has produced unprecedented clinical outcomes in the treatment of "liquid" hematologic cancers, but to date has not produced comparable responses in targeting solid malignancies. Advances in our understanding of the immunobiology of solid tumors have highlighted several hurdles which currently hinder the efficacy of this therapy. These barriers include the insufficient accumulation of CAR T-cells in the tumor due to poor trafficking or physical exclusion and the exposure of infiltrating CAR T-cells to a panoply of immune suppressive checkpoint molecules, cytokines, and metabolic stresses that are not conducive to efficient immune reactions and can thereby render these cells anergic, exhausted, or apoptotic. This mini-review summarizes these hurdles and describes some recent approaches and innovations to genetically re-engineer CAR T-cells to counter inhibitory influences found in the tumor microenvironment. Novel immunotherapy drug combinations to potentiate the activity of CAR T-cells are also discussed. As our understanding of the immune landscape of tumors improves and our repertoire of immunotherapeutic drugs expands, it is envisaged that the efficacy of CAR T-cells against solid tumors might be potentiated using combination therapies, which it is hoped may lead to meaningful improvements in clinical outcome for patients with refractory solid malignancies.

New Chimeric Antigen Receptor Design for Solid Tumors

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Research Advances in Chimeric Antigen Receptor-Modified T-cell Therapy (Review)

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

A long way to the battlefront: CAR T cell therapy against solid cancers.

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors

Innovative Strategies to Advance CAR T Cell Therapy for Solid Tumors.

Engineering Chimeric Antigen Receptor-T Cells for Cancer Treatment

Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments

Novel Strategies to Improve CAR-T Cell Efficacy by Targeting the Solid Tumor Microenvironment

Targeting the Immune-Suppressive Tumor Microenvironment to Potentiate CAR T Cell Therapy

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review